|
1
|
Ramphal R, Pappo A, Zielenska M, Grant R
and Ngan BY: Pediatric renal cell carcinoma: Clinical, pathologic,
and molecular abnormalities associated with the members of the mit
transcription factor family. Am J Clin Pathol. 126:349–364. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Komai Y, Fujiwara M, Fujii Y, Mukai H,
Yonese J, Kawakami S, Yamamoto S, Migita T, Ishikawa Y, Kurata M,
et al: Adult Xp11 translocation renal cell carcinoma diagnosed by
cytogenetics and immunohistochemistry. Clin Cancer Res.
15:1170–1176. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lopez-Beltran A, Cheng L, Vidal A,
Scarpelli M, Kirkali Z, Blanca A and Montironi R: Pathology of
renal cell carcinoma: An update. Anal Quant Cytopathol Histpathol.
35:61–76. 2013.PubMed/NCBI
|
|
4
|
Argani P, Lal P, Hutchinson B, Lui MY,
Reuter VE and Ladanyi M: Aberrant nuclear immunoreactivity for TFE3
in neoplasms with TFE3 gene fusions: A sensitive and specific
immunohistochemical assay. Am J Surg Pathol. 27:750–761. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Argani P, Antonescu CR, Illei PB, Lui MY,
Timmons CF, Newbury R, Reuter VE, Garvin AJ, Perez-Atayde AR,
Fletcher JA, et al: Primary renal neoplasms with the ASPL-TFE3 gene
fusion of alveolar soft part sarcoma: A distinctive tumor entity
previously included among renal cell carcinomas of children and
adolescents. Am J Pathol. 159:179–192. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Argani P, Olgac S, Tickoo SK, Goldfischer
M, Moch H, Chan DY, Eble JN, Bonsib SM, Jimeno M, Lloreta J, et al:
Xp11 translocation renal cell carcinoma in adults: Expanded
clinical, pathologic, and genetic spectrum. Am J Surg Pathol.
31:1149–1160. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Castellvi J, Garcia A, Ruiz-Marcellan C,
Hernández-Losa J, Peg V, Salcedo M, Gil-Moreno A, Ramon Y and Cajal
S: Cell signaling in endometrial carcinoma: Phosphorylated
4E-binding protein-1 expression in endometrial cancer correlates
with aggressive tumors and prognosis. Hum Pathol. 40:1418–1426.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Parikh J, Coleman T, Messias N and Brown
J: Temsirolimus in the treatment of renal cell carcinoma associated
with Xp11.2 translocation/TFE gene fusion proteins: A case report
and review of literature. Rare Tumors. 1:e532009.PubMed/NCBI
|
|
9
|
Choueiri TK, Lim ZD, Hirsch MS, Tamboli P,
Jonasch E, McDermott DF, Dal Cin P, Corn P, Vaishampayan U, Heng DY
and Tannir NM: Vascular endothelial growth factor-targeted therapy
for the treatment of adult metastatic Xp11.2 translocation renal
cell carcinoma. Cancer. 116:5219–5225. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rao Q, Williamson SR, Zhang S, Eble JN,
Grignon DJ, Wang M, Zhou XJ, Huang W, Tan PH, Maclennan GT and
Cheng L: TFE3 break-apart FISH has a higher sensitivity for Xp11.2
translocation-associated renal cell carcinoma compared with TFE3 or
cathepsin K immunohistochemical staining alone: Expanding the
morphologic spectrum. Am J Surg Pathol. 37:804–815. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dickson BC, Brooks JS, Pasha TL and Zhang
PJ: TFE3 expression in tumors of the microphthalmia-associated
transcription factor (MiTF) family. Int J Surg Pathol. 19:26–30.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rao Q, Guan B and Zhou XJ: Xp11.2
Translocation renal cell carcinomas have a poorer prognosis than
non-Xp11.2 translocation carcinomas in children and young adults: A
meta-analysis. Int J Surg Pathol. 18:458–464. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu L, Yang R, Gan W, Chen X, Qiu X, Fu K,
Huang J, Zhu G and Guo H: Xp11.2 translocation renal cell
carcinomas in young adults. BMC Urol. 15:572015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ploper D and De Robertis EM: The MITF
family of transcription factors: Role in endolysosomal biogenesis,
Wnt signaling, and oncogenesis. Pharmacol Res. 99:36–43. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Giangrande PH, Hallstrom TC, Tunyaplin C,
Calame K and Nevins JR: Identification of E-Box factor TFE3 as a
functional partner for the E2F3 transcription factor. Mol Cell
Biol. 23:3707–3720. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Leone G, Degregori J, Yan Z, Jakoi L,
Ishida S, Williams RS and Nevins JR: E2F3 activity is regulated
during the cell cycle and is required for the induction of S phase.
Genes Dev. 12:2120–2130. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li M, Wang Y, Yu Y, Nishizawa M, Nakajima
T, Ito S and Kannan P: The human transcription factor activation
protein-2 gamma (AP-2gamma): Gene structure, promoter and,
expression in mammary carcinoma cell lines. Gene. 301:43–51. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu Y, Wang Y, Li M and Kannan P:
Tumorigenic effect of transcription factor hAP-2alpha and the
intricate link between hAP-2alpha activation and squelching. Mol
Carcinog. 34:172–179. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Furuya N, Kamai T, Shirataki H, Yanai Y,
Fukuda T, Mizuno T, Nakamura F, Kambara T, Nakanishi K, Abe H and
Yoshida K: Serum interferon alpha receptor 2 mRNA may predict
efficacy of interferon alpha with/without low-dose sorafenib for
metastatic clear cell renal cell carcinoma. Cancer Immunol
Immunother. 60:793–808. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kamai T, Tsujii T, Arai K, Takagi K, Asami
H, Ito Y and Oshima H: Significant association of Rho/ROCK pathway
with invasion and metastasis of bladder cancer. Clin Cancer Res.
9:2632–2641. 2003.PubMed/NCBI
|
|
21
|
Pantuck AJ, Seligson DB, Klatte T, Yu H,
Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS and Figlin
RA: Prognostic relevance of the mTOR pathway in renal cell
carcinoma: Implications for molecular patient selection for
targeted therapy. Cancer. 109:2257–2267. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Argani P, Hicks J, De Marzo AM, Albadine
R, Illei PB, Ladanyi M, Reuter VE and Netto GJ: Xp11 translocation
renal cell carcinoma (RCC): Extended immunohistochemical profile
emphasizing novel RCC Markers. Am J Surg Pathol. 34:1295–1303.
2010. View Article : Google Scholar : PubMed/NCBI
|
